Introduction

18
Early diagnosis and effective treatment of malaria is central to the success of malaria control 19 programs. However, this strategy is compromised by the emergence of drug resistant 20 parasites that are well established in P. falciparum and increasingly recognised in P. vivax 21
(1, 2). The emergence of multidrug resistant parasites throughout the malaria endemic world 22 has been a driving force in the development and deployment of a variety of artemisinin-23 based combination therapies (ACT) for the treatment of falciparum malaria (3). Endorsed by 24 the World Health Organization (WHO), ACT is now first-line anti-malarial policy in over 80 25 countries. Although chloroquine (CQ) remains the treatment of choice for vivax malaria, this 26 position is increasingly under threat from the emergence and spread of CQ resistant P. vivax 27 that, in some areas, have reached high levels requiring the revision of national guidelines (2). 28
The ability of parasites to develop resistance to anti-malarial drugs is relentless, as evidenced 29 by reports of the emergence and spread of decreased in vivo and in vitro susceptibility to 30 most anti-malarial agents including the artemisinin derivatives (4, 5) and ACT combination 31 therapies (6, 7). It is imperative that the development of new and effective partner drugs is 32 maintained to ensure an armamentarium of highly effective anti-malarial treatments. 33 Naphthoquine phosphate (NQ), a 4-aminoquinoline compound first synthesized in China in 34 the 1980s, demonstrates excellent efficacy against the murine malaria parasite P. berghei and 35 CQ resistant P. falciparum (8) (9) (10) . NQ has been combined with artemisinin as a fixed-dose 36 combination therapy (ARCO ® ) with proven in vivo efficacy against falciparum (11-13) and 37 vivax malaria (14-16). Although approved and registered in more than ten countries, in vitro 38 NQ susceptibility data in clinical isolates of P. falciparum are limited, with no published ex 39
vivo data yet available for P. vivax. 40
The anti-malarial activity of the thiazine dye methylene blue (MB) was first reported at the 41 end of the 19 th century (17). Although MB's anti-malarial efficacy has been proven in 42 4 several studies over the next decades, MB was abandoned from the drug development 43 pipeline due to its low tolerability which was the result of unpleasant, but reversible adverse 44 effects (18). There is renewed interest in the use of MB in the modern era of malaria 45 therapeutics, with studies highlighting its potent schizonticidal activity against CQ resistant 46 P. falciparum (19) (20) (21) (22) (23) (24) , as well as gametocyticidal activity (25) (26) (27) . Furthermore, clinical 47 trials in Africa have shown that effective anti-plasmodial doses of MB are safe in both adults 48 and children, including G6PD-deficient individuals (28, 29) . MB has also been shown to 49 have ex vivo activity against CQ sensitive P. vivax (30), but has yet to be assessed against 50
The objectives of the current study were to examine the species-and stage-specific ex vivo 52 susceptibilities of NQ and MB in clinical field isolates of Plasmodium from an area with 53 known multidrug resistance in P. falciparum and P. vivax, and to define the cross-54 susceptibility patterns between NQ and MB and conventional anti-malarials. 
Materials and Methods
58
Field location and sample collection 59
Plasmodium isolates were collected from patients attending malaria clinics in Timika (Papua, 60 Indonesia), a region known to be endemic for P. falciparum isolates resistant to CQ, AQ, and 61 sufadoxine-pyrimethamine (SP), and P. vivax isolates resistant to CQ (31-33). Unpublished 62 clinical data from 2015 suggests that dihydroartemisinin (DHA) and PIP retain high efficacy 63 against both Plasmodium species. Patients with symptomatic malaria were recruited into the 64 study if singly infected with P. falciparum or P. vivax, with a parasitaemia of between 2,000 65 µL -1 and 80,000 µL -1 , and the majority (>70%) of parasites at ring stage of development. 66
After written consent was obtained, venous blood (5 mL) was collected and after removal of 67 host white blood cells by using cellulose filters, the packed infected red blood cells (iRBCs) 68 were used for the ex vivo drug susceptibility assay. Drug susceptibility of P. vivax and P. falciparum isolates was measured using a protocol 77 modified from the WHO microtest as described previously (33, 35, 36 To investigate the stage-specific drug susceptibility of anti-malarial action, a subgroup of 90 isolates with initially greater than 90% ring stage parasites was exposed to the drugs for 24 91 hours. The iRBCs were then washed with phosphate buffered saline using centrifugation and 92
were re-suspended in drug-free medium and cultured for another 20-24 hours before harvest 93 (i.e., ring stage assay). The same isolate was cultured for 20-24 hours in the absence of drugs 94 until 85-95% of parasites had reached trophozoite stage; these were then drug exposed for 24 95 hours until harvest (trophozoite stage assay) (33, 37) . 96
97
Quality control procedures 98
Microscopy quality control was assured by randomly selecting recordings for two drugs per 99 isolate which were read by a second microscopist. If the raw data derived by the two 100 microscopists lead to a significant shift in the IC 50 estimates of the selected drugs (i.e., more 101 than one dilution difference), the whole assay (i.e., all standard drugs and experimental 102 compounds) was re-read by a second reader and the results compared. Discrepant results 103 were resolved by a third reading by an expert microscopist. Drug plate quality was assured 104 by testing drug plates using the same methodology with P. falciparum laboratory strains K1 105 and FC27. 106 7
Data analysis 108
The dose-response data were analysed using nonlinear regression analysis (WinNonLn 4.1, 109
Pharsight Corporation) and the IC 50 value derived using an inhibitory sigmoid Emax model. 110
Ex vivo IC 50 data were only used from predicted curves where the E max and E 0 were within 111 15% of 100 and 1, respectively. Data analysis was performed using STATA (version 13.1) 112
and GraphPad Prism (version 6) Although NQ and MB were tested on different drug plate lots, quality control experiments 138 using laboratory strains and the same assay method showed no difference between drug plate 139 lots for either the standard anti-malarials, or the test compounds NQ and MB. In the MB 140 group, the median IC 50 s in P. falciparum were significantly higher compared to P. vivax for 141 AS (3.8 versus 1.7 nM, p=0.002) and MB (1.6 versus 1.2 nM, p<0.001), but lower for CQ 142 (93.7 nM versus 146.0, p<0.001), AQ (13.7 versus 23.4 versus, p<0.001), and MFQ (10.5 143 nM versus 16.8, p=0.015) . 144 NQ showed very potent activity against both species (8.0 nM in P. falciparum and 7.8 nM in 145 P. vivax), and this was significantly lower than the activities of all of the standard anti-146 malarials tested, with the exception of AS. MB exhibited excellent activity (median IC 50 s of 147 9 1.6 nM against P. falciparum and 1.2 nM against P. vivax), exceeding the activity of all 148 standard anti-malarials tested, including the artemisinin derivative AS (Table 2, Figure 1) . 149
150
Stage-specific drug activity 151
In P. vivax isolates, the median IC 50 of all drugs was significantly higher at the trophozoite 152 stage compared to the ring stage, the ratio being 1.5 to 8-fold higher for the standard anti-153 malarials and MB, and 50-fold higher for NQ (Table 3 and Figure 2) Inter-species comparisons of drug susceptibilities revealed slightly different patterns in the 176 two subgroups of isolates. Whilst these observations might suggest underlying species 177 differences in pharmacodynamic activity, the differences were of marginal magnitude and 178 may also reflect statistical chance. 
